Issue No. 059 · Story 02 · September 28, 2026

Mylan Opens New Wegovy Patent Fight

Mylan Pharmaceuticals filed a Delaware federal lawsuit seeking a declaration that its proposed generic version of Novo Nordisk's Wegovy does not infringe a patent covering administration through a single-dose pen.

§The case concerns Mylan's proposed generic version of the weight-loss medicine semaglutide.
§Mylan asks the court for a noninfringement declaration covering U.S. Patent No. 12,275,786.
§The filing adds a new patent to a broader dispute between the companies over proposed Wegovy generics.
§The complaint was filed in the U.S. District Court for the District of Delaware.

THE TAKEAWAY

The case connects patent scope to competition around one of the most recognizable weight-loss medicines in the United States. It also adds another claim set to an already active generic-drug dispute.

Source: Justia

Same issue

Apple Faces $5.7 Billion Haptics Patent Verdict

A federal jury in San Diego awarded Taction Technology more than $5.7 billion after finding that Apple's Taptic Engine infringed claims from two haptics patents used in iPhones and Apple Watches.

Patent